Noninvasive Quantification of the Pulmonary Anti-inflammatory Effect of Rosiglitazone.
Phase of Trial: Phase 0
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Rosiglitazone (Primary) ; Zileuton (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Biomarker; Pharmacodynamics
- 28 Jul 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 Jul 2011 Actual initiation date 1 Jul 2011 added as reported by ClinicalTrials.gov.
- 28 Jul 2011 Trial phase changed from I to 0 as reported by ClinicalTrials.gov.